ALB and cancer: We examined somatic mutations in depth using three approaches: pathway analysis as described in Materials and Methods (Fig 2), comparative genomics (comparing to well-curated human data), and a candidate gene analysis in which we compared mutations with an in-house curated cancer gene list including COSMIC consensus cancer genes, genes with previously described mutations in human AS and canine HSA, as well as genes residing in pathways that are affected in vascular cancers[2,13,14].